| . | . | . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|---|---|
| . | Baseline . | CPT 30 s . | CPT 2 min . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| NE (nmol/L) | ||||||||
| NT | 1.13 (0.8 –1.46) | 1.46 (0.97 –1.88) | 1.7 (1.12 –2.08) | 1.74 (1.21 –2.19) | 0.106 (P = .374) | BL vs CPT 30 s; 0.135 (P < .001) | Group: 0.141 (P = .257) | No interaction |
| HT | 1.36 (0.90 –1.18) | 1.36 (1.0 –2.07) | 1.75 (1.21 –2.72) | 1.85 (1.22 –2.63) | BL vs CPT 2 min: 0.352 (P < .001) | BL vs CPT 30 s: 0.181 (P < .001) | CPT 30 s: –0.105 (P = .069) | |
| BL vs after CPT 0.379 (P < .001) | BL vs CPT 2 min: 0.357 (P < .001) | CPT 2 min: –0.011 (P = .846) | ||||||
| BL vs after CPT: 0.396 (P < .001) | After CPT: –0.038 (P = .512) | |||||||
| E (nmol/L) | ||||||||
| NT | 0.11 (0.07 –0.18) | 0.13 (0.08 –0.19) | 0.15 (0.1 –0.22) | 0.13 (0.09 –0.19) | –0.405 (P = .005) | BL vs CPT 30 s: 0.144 (P = .070) | Group: –0.400 (P = .021) | No interaction |
| HT | 0.07 (0.04 –0.12) | 0.08 (0.05 –0.11) | 0.10 (0.07 –0.15) | 0.10 (0.06 –0.14) | BL vs CPT <2 min: 0.401 (P < .001) | BL vs CPT 30 s: 0.197 (P = .062) | CPT 30 s: –0.122 (P = .443) | |
| BL vs after CPT: 0.234 (P = .003) | BL vs CPT 2 min: 0.431 (P < .001) | CPT 2 min: –0.065 (P = .682) | ||||||
| BL vs after CPT: 0.164 (P = .123) | After CPT: 0.155 (P = .325) | |||||||
| NPY 1–36 (pM) | ||||||||
| NT | 0.13 (0.12 –0.18) | 0.13 (0.12 –0.2) | 0.18 (0.13 –0.25) | 0.19 (0.13 –0.26) | 0.287 (P < .001) | BL vs CPT 30 s: 0.044 (P = .424) | Group: 0.297 (P = .004) | No interaction |
| HT | 0.20 (0.15 –0.28) | 0.23 (0.17 –0.29) | 0.23 (0.17 –0.34) | 0.21 (0.14 –0.34) | BL vs CPT 2 min: 0.194 (P < .001) | BL vs CPT 30 s: 0.013 (P = .858) | CPT 30 s: 0.071 (P = .520) | |
| BL vs after CPT: 0.180 (P = .001) | BL vs CPT 2 min: 0.197 (P = .008) | CPT 2 min: –0.011 (P = .919) | ||||||
| BL vs after CPT: 0.226 (P = .002) | After CPT: –0.103 (P = .348) | |||||||
| . | . | . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|---|---|
| . | Baseline . | CPT 30 s . | CPT 2 min . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| NE (nmol/L) | ||||||||
| NT | 1.13 (0.8 –1.46) | 1.46 (0.97 –1.88) | 1.7 (1.12 –2.08) | 1.74 (1.21 –2.19) | 0.106 (P = .374) | BL vs CPT 30 s; 0.135 (P < .001) | Group: 0.141 (P = .257) | No interaction |
| HT | 1.36 (0.90 –1.18) | 1.36 (1.0 –2.07) | 1.75 (1.21 –2.72) | 1.85 (1.22 –2.63) | BL vs CPT 2 min: 0.352 (P < .001) | BL vs CPT 30 s: 0.181 (P < .001) | CPT 30 s: –0.105 (P = .069) | |
| BL vs after CPT 0.379 (P < .001) | BL vs CPT 2 min: 0.357 (P < .001) | CPT 2 min: –0.011 (P = .846) | ||||||
| BL vs after CPT: 0.396 (P < .001) | After CPT: –0.038 (P = .512) | |||||||
| E (nmol/L) | ||||||||
| NT | 0.11 (0.07 –0.18) | 0.13 (0.08 –0.19) | 0.15 (0.1 –0.22) | 0.13 (0.09 –0.19) | –0.405 (P = .005) | BL vs CPT 30 s: 0.144 (P = .070) | Group: –0.400 (P = .021) | No interaction |
| HT | 0.07 (0.04 –0.12) | 0.08 (0.05 –0.11) | 0.10 (0.07 –0.15) | 0.10 (0.06 –0.14) | BL vs CPT <2 min: 0.401 (P < .001) | BL vs CPT 30 s: 0.197 (P = .062) | CPT 30 s: –0.122 (P = .443) | |
| BL vs after CPT: 0.234 (P = .003) | BL vs CPT 2 min: 0.431 (P < .001) | CPT 2 min: –0.065 (P = .682) | ||||||
| BL vs after CPT: 0.164 (P = .123) | After CPT: 0.155 (P = .325) | |||||||
| NPY 1–36 (pM) | ||||||||
| NT | 0.13 (0.12 –0.18) | 0.13 (0.12 –0.2) | 0.18 (0.13 –0.25) | 0.19 (0.13 –0.26) | 0.287 (P < .001) | BL vs CPT 30 s: 0.044 (P = .424) | Group: 0.297 (P = .004) | No interaction |
| HT | 0.20 (0.15 –0.28) | 0.23 (0.17 –0.29) | 0.23 (0.17 –0.34) | 0.21 (0.14 –0.34) | BL vs CPT 2 min: 0.194 (P < .001) | BL vs CPT 30 s: 0.013 (P = .858) | CPT 30 s: 0.071 (P = .520) | |
| BL vs after CPT: 0.180 (P = .001) | BL vs CPT 2 min: 0.197 (P = .008) | CPT 2 min: –0.011 (P = .919) | ||||||
| BL vs after CPT: 0.226 (P = .002) | After CPT: –0.103 (P = .348) | |||||||
Data are presented as median (interquartile range).
BL, baseline.
| . | . | . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|---|---|
| . | Baseline . | CPT 30 s . | CPT 2 min . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| NE (nmol/L) | ||||||||
| NT | 1.13 (0.8 –1.46) | 1.46 (0.97 –1.88) | 1.7 (1.12 –2.08) | 1.74 (1.21 –2.19) | 0.106 (P = .374) | BL vs CPT 30 s; 0.135 (P < .001) | Group: 0.141 (P = .257) | No interaction |
| HT | 1.36 (0.90 –1.18) | 1.36 (1.0 –2.07) | 1.75 (1.21 –2.72) | 1.85 (1.22 –2.63) | BL vs CPT 2 min: 0.352 (P < .001) | BL vs CPT 30 s: 0.181 (P < .001) | CPT 30 s: –0.105 (P = .069) | |
| BL vs after CPT 0.379 (P < .001) | BL vs CPT 2 min: 0.357 (P < .001) | CPT 2 min: –0.011 (P = .846) | ||||||
| BL vs after CPT: 0.396 (P < .001) | After CPT: –0.038 (P = .512) | |||||||
| E (nmol/L) | ||||||||
| NT | 0.11 (0.07 –0.18) | 0.13 (0.08 –0.19) | 0.15 (0.1 –0.22) | 0.13 (0.09 –0.19) | –0.405 (P = .005) | BL vs CPT 30 s: 0.144 (P = .070) | Group: –0.400 (P = .021) | No interaction |
| HT | 0.07 (0.04 –0.12) | 0.08 (0.05 –0.11) | 0.10 (0.07 –0.15) | 0.10 (0.06 –0.14) | BL vs CPT <2 min: 0.401 (P < .001) | BL vs CPT 30 s: 0.197 (P = .062) | CPT 30 s: –0.122 (P = .443) | |
| BL vs after CPT: 0.234 (P = .003) | BL vs CPT 2 min: 0.431 (P < .001) | CPT 2 min: –0.065 (P = .682) | ||||||
| BL vs after CPT: 0.164 (P = .123) | After CPT: 0.155 (P = .325) | |||||||
| NPY 1–36 (pM) | ||||||||
| NT | 0.13 (0.12 –0.18) | 0.13 (0.12 –0.2) | 0.18 (0.13 –0.25) | 0.19 (0.13 –0.26) | 0.287 (P < .001) | BL vs CPT 30 s: 0.044 (P = .424) | Group: 0.297 (P = .004) | No interaction |
| HT | 0.20 (0.15 –0.28) | 0.23 (0.17 –0.29) | 0.23 (0.17 –0.34) | 0.21 (0.14 –0.34) | BL vs CPT 2 min: 0.194 (P < .001) | BL vs CPT 30 s: 0.013 (P = .858) | CPT 30 s: 0.071 (P = .520) | |
| BL vs after CPT: 0.180 (P = .001) | BL vs CPT 2 min: 0.197 (P = .008) | CPT 2 min: –0.011 (P = .919) | ||||||
| BL vs after CPT: 0.226 (P = .002) | After CPT: –0.103 (P = .348) | |||||||
| . | . | . | . | . | Univariate analysis . | Adjusted analysis . | ||
|---|---|---|---|---|---|---|---|---|
| . | Baseline . | CPT 30 s . | CPT 2 min . | After CPT . | Group β (P-value) . | Exposure β (P-value) . | β (P-value) . | Group × exposure β (P-value) . |
| NE (nmol/L) | ||||||||
| NT | 1.13 (0.8 –1.46) | 1.46 (0.97 –1.88) | 1.7 (1.12 –2.08) | 1.74 (1.21 –2.19) | 0.106 (P = .374) | BL vs CPT 30 s; 0.135 (P < .001) | Group: 0.141 (P = .257) | No interaction |
| HT | 1.36 (0.90 –1.18) | 1.36 (1.0 –2.07) | 1.75 (1.21 –2.72) | 1.85 (1.22 –2.63) | BL vs CPT 2 min: 0.352 (P < .001) | BL vs CPT 30 s: 0.181 (P < .001) | CPT 30 s: –0.105 (P = .069) | |
| BL vs after CPT 0.379 (P < .001) | BL vs CPT 2 min: 0.357 (P < .001) | CPT 2 min: –0.011 (P = .846) | ||||||
| BL vs after CPT: 0.396 (P < .001) | After CPT: –0.038 (P = .512) | |||||||
| E (nmol/L) | ||||||||
| NT | 0.11 (0.07 –0.18) | 0.13 (0.08 –0.19) | 0.15 (0.1 –0.22) | 0.13 (0.09 –0.19) | –0.405 (P = .005) | BL vs CPT 30 s: 0.144 (P = .070) | Group: –0.400 (P = .021) | No interaction |
| HT | 0.07 (0.04 –0.12) | 0.08 (0.05 –0.11) | 0.10 (0.07 –0.15) | 0.10 (0.06 –0.14) | BL vs CPT <2 min: 0.401 (P < .001) | BL vs CPT 30 s: 0.197 (P = .062) | CPT 30 s: –0.122 (P = .443) | |
| BL vs after CPT: 0.234 (P = .003) | BL vs CPT 2 min: 0.431 (P < .001) | CPT 2 min: –0.065 (P = .682) | ||||||
| BL vs after CPT: 0.164 (P = .123) | After CPT: 0.155 (P = .325) | |||||||
| NPY 1–36 (pM) | ||||||||
| NT | 0.13 (0.12 –0.18) | 0.13 (0.12 –0.2) | 0.18 (0.13 –0.25) | 0.19 (0.13 –0.26) | 0.287 (P < .001) | BL vs CPT 30 s: 0.044 (P = .424) | Group: 0.297 (P = .004) | No interaction |
| HT | 0.20 (0.15 –0.28) | 0.23 (0.17 –0.29) | 0.23 (0.17 –0.34) | 0.21 (0.14 –0.34) | BL vs CPT 2 min: 0.194 (P < .001) | BL vs CPT 30 s: 0.013 (P = .858) | CPT 30 s: 0.071 (P = .520) | |
| BL vs after CPT: 0.180 (P = .001) | BL vs CPT 2 min: 0.197 (P = .008) | CPT 2 min: –0.011 (P = .919) | ||||||
| BL vs after CPT: 0.226 (P = .002) | After CPT: –0.103 (P = .348) | |||||||
Data are presented as median (interquartile range).
BL, baseline.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
